Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Elutia Inc. secures $15 million in debt financing from Avenue Capital Group to support the launch of NXT-41x, targeting the $1.5 billion plastic and reconstructive surgery market.

PUBLIC · ELUTAug 13, 2026•2 days ago

Amount Raised

$15 Million

Round Type

Debt Financing

Silver SpringBiotechnology

Investors

Avenue Capital Group

Description

Elutia Inc. has announced a $15 million growth capital financing agreement with Avenue Capital Group. This funding aims to strengthen Elutia's balance sheet and support the development of its next-generation antibiotic-eluting biomatrix, NXT-41x. FDA clearance for NXT-41x is anticipated in the first half of 2027

Company Information

Company

Elutia

Location

12510 PROSPERITY DRIVE

Silver Spring, Maryland, United States

About

Elutia is a company that specializes in advanced biomaterials and is known for its innovative solutions in the medical device sector. They focus on developing technologies that enhance patient care and outcomes. Their bioenvelope technology is designed to protect patients receiving implantable devices. Elutia is committed to improving healthcare through their advancements.

Don't miss Elutia's next move

Get an email the moment Elutia raises, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you

1 contact

Verified contacts25 people are listed at Elutia — we don't have their email yet.

Predictive Intelligence

Strategic

ML-powered predictions for Elutia's next move

Learn about Strategic plan

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech